Zymride 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Zymride 2 is typically prescribed as an adjunct to diet and exercise when these measures alone do not achieve adequate blood glucose regulation. The medication helps lower both fasting and postprandial blood glucose levels, contributing to the reduction of long-term diabetic complications. Dosage should be individualized based on the patient’s glycemic response and tolerance, with careful monitoring to minimize the risk of hypoglycemia, the most common adverse effect. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients. Zymride 2 is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function are recommended during therapy. Patients should be educated on recognizing symptoms of hypoglycemia and maintaining consistent dietary habits to optimize therapeutic outcomes.